Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Average Recommendation of “Moderate Buy” by Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has received an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $23.3571.

A number of brokerages recently weighed in on CMPS. Oppenheimer reissued an “outperform” rating on shares of Compass Pathways in a research note on Wednesday, August 5th. B. Riley Financial increased their price target on Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Canaccord Genuity Group lifted their price objective on Compass Pathways from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Royal Bank Of Canada lowered their price objective on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, Stifel Nicolaus boosted their price objective on Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $14.35 on Friday. The stock has a market capitalization of $1.99 billion, a PE ratio of -3.11 and a beta of 2.54. The business’s 50 day simple moving average is $13.12 and its 200 day simple moving average is $10.57. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. Compass Pathways has a one year low of $4.82 and a one year high of $15.87.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, research analysts forecast that Compass Pathways will post -1.26 earnings per share for the current year.

Hedge Funds Weigh In On Compass Pathways

Several institutional investors have recently added to or reduced their stakes in CMPS. EverSource Wealth Advisors LLC boosted its holdings in shares of Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after buying an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Compass Pathways in the 4th quarter valued at $38,000. Parallel Advisors LLC lifted its position in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after acquiring an additional 7,183 shares during the period. Advisory Services Network LLC acquired a new position in shares of Compass Pathways during the 3rd quarter valued at $41,000. Finally, North Star Investment Management Corp. boosted its stake in Compass Pathways by 1,354.0% during the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after acquiring an additional 7,000 shares in the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

Compass Pathways Company Profile

Compass Pathways plc (NASDAQ: CMPS) is a biotechnology company developing novel treatments for mental health conditions. The company’s primary focus is psilocybin therapy, which combines a proprietary investigational formulation with psychological support delivered by trained therapists.

Its lead candidate, COMP360, is a synthetic crystalline formulation of psilocybin being studied primarily for treatment-resistant depression. Compass Pathways has conducted mid- and late-stage clinical trials evaluating COMP360 and has also investigated its potential use in other difficult-to-treat psychiatric conditions, including post-traumatic stress disorder and anorexia nervosa.